Sulforaphane Modulates the Inflammation and Delays Neurodegeneration on a Retinitis Pigmentosa Mice Model.

glial cells neuroinflammation rd10 retinitis pigmentosa sulforaphane

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2022
Historique:
received: 08 11 2021
accepted: 03 01 2022
entrez: 18 3 2022
pubmed: 19 3 2022
medline: 19 3 2022
Statut: epublish

Résumé

The term retinitis pigmentosa (RP) describes a large group of hereditary retinopathies. From a cellular view, retinal degeneration is prompted by an initial death of rods, followed later by cone degeneration. This cellular progressive degeneration is translated clinically in tunnel vision, which evolves to complete blindness. The mechanism underlying the photoreceptor degeneration is unknown, but several mechanisms have been pointed out as main co-stars, inflammation being one of the most relevant. Retinal inflammation is characterized by proliferation, migration, and morphological changes in glial cells, in both microglia and Müller cells, as well as the increase in the expression of inflammatory mediators. Retinal inflammation has been reported in several animal models and clinical cases of RP, but the specific role that inflammation plays in the pathology evolution remains uncertain. Sulforaphane (SFN) is an antioxidant natural compound that has shown anti-inflammatory properties, including the modulation of glial cells activation. The present work explores the effects of SFN on retinal degeneration and inflammation, analyzing the modulation of glial cells in the RP rd10 mice model. A daily dose of 20 mg/kg of sulforaphane was administered intraperitoneally to control (C57BL/6J wild type) and rd10 (Pde6brd10) mice, from postnatal day 14 to day 20. On postnatal day 21, euthanasia was performed. Histological retina samples were used to assess cellular degeneration, Müller cells, and microglia activation. SFN administration delayed the loss of photoreceptors. It also ameliorated the characteristic reactive gliosis, assessed by retinal GFAP expression. Moreover, sulforaphane treatment regulated the microglia activation state, inducing changes in the microglia morphology, migration, and expression through the retina. In addition, SFN modulated the expression of the interleukins 1β, 4, Ym1, and arginase inflammatory mediators. Surprisingly, M2 polarization marker expression was increased at P21 and was reduced by SFN treatment. To summarize, SFN administration reduced retinal neurodegeneration and modified the inflammatory profile of RP, which may contribute to the SFN neuroprotective effect.

Identifiants

pubmed: 35300301
doi: 10.3389/fphar.2022.811257
pii: 811257
pmc: PMC8921528
doi:

Types de publication

Journal Article

Langues

eng

Pagination

811257

Informations de copyright

Copyright © 2022 Canto, Martínez-González, Miranda, Olivar, Almansa and Hernández-Rabaza.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Pharm Res. 2011 Dec;28(12):3171-9
pubmed: 21681606
Curr Eye Res. 2017 Dec;42(12):1684-1688
pubmed: 28937835
J Vis Exp. 2018 Jun 5;(136):
pubmed: 29939190
Prog Retin Eye Res. 2018 Jan;62:24-37
pubmed: 28962928
PLoS One. 2019 Apr 3;14(4):e0214674
pubmed: 30943234
Nature. 2008 Jul 24;454(7203):428-35
pubmed: 18650913
Endocr Relat Cancer. 2018 Mar;25(3):255-268
pubmed: 29431641
Curr Mol Pharmacol. 2018;11(3):237-253
pubmed: 29376497
Orphanet J Rare Dis. 2006 Oct 11;1:40
pubmed: 17032466
Trends Pharmacol Sci. 2015 Jun;36(6):395-405
pubmed: 25930708
Mol Neurodegener. 2017 Apr 24;12(1):31
pubmed: 28438165
EMBO J. 2002 Mar 1;21(5):857-64
pubmed: 11867514
J Neurosci Res. 2013 Sep;91(9):1143-51
pubmed: 23686747
Exp Gerontol. 2016 Jan;73:42-8
pubmed: 26571201
J Neuroimmunol. 1994 Nov;55(1):91-7
pubmed: 7962485
Cells. 2019 Feb 22;8(2):
pubmed: 30813369
Antioxidants (Basel). 2019 Mar 02;8(3):
pubmed: 30832304
Curr Opin Pediatr. 2018 Dec;30(6):725-733
pubmed: 30234647
Exp Anim. 2019 May 8;68(2):221-231
pubmed: 30606939
Autophagy. 2021 Apr;17(4):872-887
pubmed: 32138578
Front Immunol. 2019 Jul 16;10:1618
pubmed: 31379825
J Leukoc Biol. 2016 Jan;99(1):189-99
pubmed: 26269198
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10446-51
pubmed: 15229324
Biochim Biophys Acta. 2016 Sep;1862(9):1663-74
pubmed: 27267343
Int J Mol Sci. 2021 Aug 16;22(16):
pubmed: 34445510
J Neuroinflammation. 2014 Jul 26;11:133
pubmed: 25064005
PLoS One. 2014 Dec 03;9(12):e114186
pubmed: 25470382
J Neuroinflammation. 2021 Dec 24;18(1):303
pubmed: 34952606
Sci Rep. 2015 Jul 14;5:11764
pubmed: 26170250
Glia. 2016 Sep;64(9):1479-91
pubmed: 27314452
J Med Food. 2019 Feb;22(2):121-126
pubmed: 30372361
Lancet. 2006 Nov 18;368(9549):1795-809
pubmed: 17113430
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419861777
pubmed: 31266422
Exp Eye Res. 2019 Jan;178:228-237
pubmed: 29608906
J Neural Transm (Vienna). 2018 May;125(5):781-795
pubmed: 28534174
J Neuroinflammation. 2016 Apr 18;13(1):83
pubmed: 27090509
Oxid Med Cell Longev. 2013;2013:413024
pubmed: 24187606
Int J Mol Sci. 2020 Jul 06;21(13):
pubmed: 32640524
J Steroid Biochem Mol Biol. 2019 May;189:291-301
pubmed: 30654106
Immunol Lett. 2021 May;233:20-30
pubmed: 33711331
Int J Mol Sci. 2021 Oct 28;22(21):
pubmed: 34769100

Auteurs

Antolín Canto (A)

Department of Biomedical Sciences, Faculty of Health Sciences, Institute of Biomedical Sciences, Cardenal Herrera-CEU University, CEU Universities, Valencia, Spain.

Javier Martínez-González (J)

Department of Biomedical Sciences, Faculty of Health Sciences, Institute of Biomedical Sciences, Cardenal Herrera-CEU University, CEU Universities, Valencia, Spain.

María Miranda (M)

Department of Biomedical Sciences, Faculty of Health Sciences, Institute of Biomedical Sciences, Cardenal Herrera-CEU University, CEU Universities, Valencia, Spain.

Teresa Olivar (T)

Department of Biomedical Sciences, Faculty of Health Sciences, Institute of Biomedical Sciences, Cardenal Herrera-CEU University, CEU Universities, Valencia, Spain.

Inma Almansa (I)

Department of Biomedical Sciences, Faculty of Health Sciences, Institute of Biomedical Sciences, Cardenal Herrera-CEU University, CEU Universities, Valencia, Spain.

Vicente Hernández-Rabaza (V)

Department of Biomedical Sciences, Faculty of Health Sciences, Institute of Biomedical Sciences, Cardenal Herrera-CEU University, CEU Universities, Valencia, Spain.

Classifications MeSH